22 August 2017
Visiongain’s new report Global Electroceutical Market Forecast 2017-2027: Revenue Prospects by Product Type (Implantable and Non-Invasive), Product (ICD, Cochlear Implant, Spinal Cord Stimulator, Vagus Nerve Stimulator, Sacral Nerve Stimulator, Cardiac Pacemaker, Deep Brain Stimulator, Retinal Implant) and Geography indicates that the Electroceutical market will see over $19bn in revenue in 2017.
The lead analyst of the report said:
“Electroceutical technology utilizes devices that bring about a change in the nervous system by modulating brain activity. The treatment delivered by neurostimulation devices brings about life changing transformation in patients who fail to respond to traditional approaches. The opportunities to development new therapies for a wide variety of neurological and psychological conditions are attracting a lot of companies, start-ups, and investments.
Factors driving the electroceutical devices market include a projected increase in patients with chronic pain, neurological diseases, psychiatric conditions, cardiology conditions, improvements in technology such as miniaturization, better battery technology, wearable, wireless micro-current stimulation are all contributing to growth of electroceutical devices market. With respect to shocking areas of neural tissue to elicit a desired response, electrical devices so far have been clunky and imprecise. Advancement of this technology within its wide application areas shows that electroceutical devices market has vast opportunities in the coming years.”
The 149-page report contains 79 tables, charts and graphs that add visual analysis in order to explain developing trends within the Electroceutical market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading Electroceutical submarkets, segmented by product type, with forecasts for implantable and non-invasive electroceutical devices. The market is also segmented by product, with forecasts for Implantable Cardioverter Defibrillators, Cochlear Implants, Spinal Cord Stimulators, Vagus Nerve Stimulators, Sacral Nerve Stimulators, Cardiac Pacemakers, Deep Brain Stimulators and Retinal Implants.
The 157-page report offers market forecasts and analysis for 3 regional and 12 national markets. In addition, the report contains a dedicated leading companies’ chapter covering 5 companies leading the field in Electroceutical technology in detail.
The Global Electroceutical Market Forecast 2017-2027: Revenue Prospects by Product Type (Implantable and Non-Invasive), Product (ICD, Cochlear Implant, Spinal Cord Stimulator, Vagus Nerve Stimulator, Sacral Nerve Stimulator, Cardiac Pacemaker, Deep Brain Stimulator, Retinal Implant) and Geography report will be of value to anyone who wants to better understand the electroceutical device market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the electrosurgical energy device industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.